PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy

被引：19

作者：

Bocanegra, Ana ^{[1
]}

Blanco, Ester ^{[1
]}

Fernandez-Hinojal, Gonzalo ^{[2
]}

Arasanz, Hugo ^{[1
]}

Chocarro, Luisa ^{[1
]}

Zuazo, Miren ^{[1
]}

Morente, Pilar ^{[1
]}

Vera, Ruth ^{[2
]}

Escors, David ^{[1
]}

Kochan, Grazyna ^{[1
]}

机构：

[1] IdISNA, Oncoimmunol Grp, Biomed Res Ctr Navarrabiomed UPNA, Irunlarrea 3, Pamplona 31008, Spain

[2] Complejo Hosp Navarra, IdISNA, Dept Oncol, Irunlarrea 3, Pamplona 31008, Spain

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 16期

关键词：

PD-L1; immunotherapy; immune; checkpoint inhibition; systemic myeloid subsets; liquid biopsy; biomarkers; CELL LUNG-CANCER; DEATH-LIGAND; CIRCULATING TUMOR-CELLS; NATURAL-KILLER-CELLS; SOLUBLE PD-L1; T-CELLS; DENDRITIC CELLS; OPEN-LABEL; NONCLASSICAL MONOCYTES; CLINICAL-SIGNIFICANCE;

D O I：

10.3390/ijms21165918

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients undergoing these immunotherapy treatments, the only clinically accepted biomarker with some prediction capabilities for the outcome of the treatment is PD-L1 expression in tumor biopsies. Nevertheless, even when having PD-L1-positive tumors, numerous patients do not respond to these treatments. Considering the high cost of these therapies and the risk of immune-related adverse events during therapy, it is necessary to identify additional biomarkers that would facilitate stratifying patients in potential responders and non-responders before the start of immunotherapies. Here, we review the utility of PD-L1 expression not only in tumor cells but in immune system cells and their influence on the antitumor activity of immune cell subsets.

引用

页码：1 / 17

页数：17

共 105 条

[31] PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab [J].

Guibert, Nicolas ;

Delaunay, Myriam ;

Lusque, Annelle ;

Boubekeur, Nadia ;

Rouquette, Isabelle ;

Clermont, Estelle ;

Mourlanette, Jean ;

Gouin, Sandrine ;

Dormoy, Inge ;

Favre, Gilles ;

Mazieres, Julien ;

Pradines, Anne .

LUNG CANCER, 2018, 120 :108-112

[32] Tumor-derived exosomes modulate PD-L1 expression in monocytes [J].

Haderk, Franziska ;

Schulz, Ralph ;

Iskar, Murat ;

Cid, Laura Llao ;

Worst, Thomas ;

Willmund, Karolin V. ;

Schulz, Angela ;

Warnken, Uwe ;

Seiler, Jana ;

Benner, Axel ;

Nessling, Michelle ;

Zenz, Thorsten ;

Gobel, Maria ;

Durig, Jan ;

Diederichs, Sven ;

Paggetti, Jerome ;

Moussay, Etienne ;

Stilgenbauer, Stephan ;

Zapatka, Marc ;

Lichter, Peter ;

Seiffert, Martina .

SCIENCE IMMUNOLOGY, 2017, 2 (13)

[33] Patrolling monocytes control tumor metastasis to the lung [J].

Hanna, Richard N. ;

Cekic, Caglar ;

Sag, Duygu ;

Tacke, Robert ;

Thomas, Graham D. ;

Nowyhed, Heba ;

Herrley, Erica ;

Rasquinha, Nicole ;

McArdle, Sara ;

Wu, Runpei ;

Peluso, Esther ;

Metzger, Daniel ;

Ichinose, Hiroshi ;

Shaked, Iftach ;

Chodaczek, Grzegorz ;

Biswas, Subhra K. ;

Hedrick, Catherine C. .

SCIENCE, 2015, 350 (6263) :985-990

[34]

Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/s1470-2045(16)30624-6, 10.1016/S1470-2045(16)30624-6]

[35] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[36] Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? [J].

Hofman, P. ;

Heeke, S. ;

Alix-Panabieres, C. ;

Pantel, K. .

ANNALS OF ONCOLOGY, 2019, 30 (09) :1448-1459

[37] Circulating tumor cell clusters: What we know and what we expect (Review) [J].

Hong, Yupeng ;

Fang, Francia ;

Zhang, Qi .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (06) :2206-2216

[38] Increased expression of Fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma [J].

Hyakudomi, Miki ;

Matsubara, Takeshi ;

Hyakudomi, Ryoji ;

Yamamoto, Tetsu ;

Kinugasa, Shoichi ;

Yamanoi, Akira ;

Maruyama, Riruke ;

Tanaka, Tsuneo .

ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (06) :1775-1782

[39] Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer [J].

Ilie, M. ;

Szafer-Glusman, E. ;

Hofman, V. ;

Chamorey, E. ;

Lalvee, S. ;

Selva, E. ;

Leroy, S. ;

Marquette, C. -H. ;

Kowanetz, M. ;

Hedge, P. ;

Punnoose, E. ;

Hofman, P. .

ANNALS OF ONCOLOGY, 2018, 29 (01) :193-199

[40] Predictors of responses to immune checkpoint blockade in advanced melanoma [J].

Jacquelot, N. ;

Roberti, M. P. ;

Enot, D. P. ;

Rusakiewicz, S. ;

Ternes, N. ;

Jegou, S. ;

Woods, D. M. ;

Sodre, A. L. ;

Hansen, M. ;

Meirow, Y. ;

Sade-Feldman, M. ;

Burra, A. ;

Kwek, S. S. ;

Flament, C. ;

Messaoudene, M. ;

Duong, C. P. M. ;

Chen, L. ;

Kwon, B. S. ;

Anderson, A. C. ;

Kuchroo, V. K. ;

Weide, B. ;

Aubin, F. ;

Borg, C. ;

Dalle, S. ;

Beatrix, O. ;

Ayyoub, M. ;

Balme, B. ;

Tomasic, G. ;

Di Giacomo, A. M. ;

Maio, M. ;

Schadendorf, D. ;

Melero, I. ;

Dreno, B. ;

Khammari, A. ;

Dummer, R. ;

Levesque, M. ;

Koguchi, Y. ;

Fong, L. ;

Lotem, M. ;

Baniyash, M. ;

Schmidt, H. ;

Svane, I. M. ;

Kroemer, G. ;

Marabelle, A. ;

Michiels, S. ;

Cavalcanti, A. ;

Smyth, M. J. ;

Weber, S. ;

Eggermont, A. M. ;

Zitvogel, L. .

NATURE COMMUNICATIONS, 2017, 8

← 1 2 3 4 5 6 7 8 9 10 →